American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (Trial in progress)
    Meeting Abstract

    Alencar, A. J.; Roeker, L. E.; Hoffman, M.; Murthy, G. S. G.; Patel, V.; Ku, N. C.; Pauff, J. M.; Eyre, T. A.; Jurczak, W.; Le Gouill, S.
    Blood (2021)

    Fulltext@MSK | Save
  • Trial in progress: Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations
    Meeting Abstract

    Andorsky, D.; Tomassetti, S.; Deutsch, Y. E.; Broun, E. R.; Issa, G. C.; Levy, M. Y.; Deininger, M. W.; Maegawa, R.; Shrestha, A.; Mauro, M. J.
    Blood (2021)

    Fulltext@MSK | Save
  • Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL)
    Meeting Abstract

    Abramson, J. S.; Palomba, M. L.; Gordon, L. I.; Lunning, M. A.; Wang, M.; Arnason, J. E.; Purev, E.; Maloney, D. G.; Andreadis, C.; Sehgal, A. R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 study of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive or Ph-like acute lymphoblastic leukemia (ALL) (with dasatinib sensitive fusions/ mutations)
    Meeting Abstract

    Advani, A.; Moseley, A.; O'Dwyer, K.; Wood, B.; Park, J. H.; Wieduwilt, M.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • JSP191 As a single-agent conditioning regimen results in successful engraftment, donor myeloid chimerism, and production of donor derived naive lymphocytes in patients with severe combined immunodeficiency (SCID)
    Meeting Abstract

    Agarwa, R.; Dvorak, C. C.; Prockop, S.; Kwon, H. S.; Long-Boyle, J. R.; Le, A.; Brown, J. W.; Merkel, E.; Truong, K.; Velasco, B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma
    Meeting Abstract

    Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation for older patients
    Review

    Lin, R. J.; Artz, A. S.
    Hematology-American Society of Hematology Education Program (2021)

    Fulltext@MSK | Save
  • Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: Final data
    Journal Article

    Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Journal Article

    Forlenza, C. J.; Gulati, N.; Mauguen, A.; Absalon, M. J.; Castellino, S. M.; Franklin, A.; Keller, F. G.; Shukla, N.
    Blood Advances (2021)

    Fulltext@MSK | Save